SOZO(TM) Launched - First Product for Health and Wellness Markets
PR Newswire - Thu Aug 11, 11:08AM CDT
ImpediMed Limited (ASX: IPD) announced today that SOZO(TM), the first product on its new population health platform that allows consumers and patients to measure and track their body composition, fluid status and hydration in a variety of settings, is available for global pre-order at www.hellosozo.com.
IPD: 36.28 (unch)
Scripps to use SOZO in Heart Failure Study
PR Newswire - Wed Aug 10, 9:22AM CDT
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced that Scripps Health will use the SOZOTM device in a validation study for monitoring patients with heart failure who are currently being tracked using pulmonary artery pressure monitoring. The validation study will provide real-world data necessary for the final design of the pivotal trial.
IPD: 36.28 (unch)
FDA Releases Important Information Focused on Digital Health
PR Newswire - Tue Aug 09, 9:05AM CDT
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced that the U.S. Food and Drug Administration (FDA) has issued new guidance surrounding digital health.
IPD: 36.28 (unch)
ImpediMed Changes to Board of Directors
PR Newswire - Mon Aug 08, 6:15PM CDT
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced several changes to its Board of Directors.
IPD: 36.28 (unch)
ImpediMed Presents at Bioshares Biotech Summit 2016
PR Newswire - Fri Jul 29, 11:07AM CDT
ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, announced that Managing Director and CEO, Richard Carreon, presented at the Bioshares Biotech Summit 2016 in Queenstown, New Zealand, on Friday, July 29, 2016.
IPD: 36.28 (unch)
ImpediMed and Mayo Clinic Sign Joint Development Agreement
PR Newswire - Thu Jul 28, 8:27AM CDT
ImpediMed Limited (ASX: IPD) announced today that it has entered into a three-year joint development agreement with Mayo Clinic to advance new solutions for its fluid status and body composition monitoring technology in additional disease indications.
IPD: 36.28 (unch)
Australian Medical Technology Company Opens Minnesota Office
PR Newswire - Wed Jun 08, 10:00AM CDT
Australian-based medical technology company ImpediMed Limited (ASX: IPD) announced today the opening of a regional office in Bloomington, Minn., and the addition of two Minnesota medical technology veterans - Ann Holder and Jack Cosentino - to its executive leadership team.
MDT: 86.85 (-0.61), IPD: 36.28 (unch)
ImpediMed Signs Five Year, Multi-Location Clinical Trial Agreement with Mayo Clinic
PR Newswire - Tue May 31, 9:15AM CDT
ImpediMed Limited (ASX: IPD) announced today that it has entered into a five year master clinical trial agreement with Mayo Clinic to explore additional indications for its fluid status and body composition monitoring technology.
IPD: 36.28 (unch)
ImpediMed completes A$75 million Private Placement
PR Newswire - Tue Mar 22, 10:07AM CDT
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, announced the completion of its recent capital raising activity, raising a total of A$75.1 million before costs.
IPD: 36.28 (unch)
ImpediMed Establishes Medical Advisory Board for Chronic Heart Failure
PR Newswire - Mon Jan 11, 11:30AM CST
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, announced today that it has entered into agreements to establish a Medical Advisory Board to advise the Company on the design of clinical trials for the use of bioimpedance spectroscopy (BIS) in fluid detection for chronic heart failure patients.
IPD: 36.28 (unch)
ImpediMed Announces U.S. Commercial Launch of L-Dex® System for Assessment of Lymphedema in Cancer Survivors
PR Newswire - Thu Jan 07, 12:51PM CST
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, has announced the U.S. commercial launch of its L-Dex® system to aid in the clinical assessment of lymphedema.
IPD: 36.28 (unch)